Drug Profile
ASLAN 005
Alternative Names: ASLAN 005Latest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator Agency for Science, Technology and Research
- Class Antibodies; Antineoplastics
- Mechanism of Action RON protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Sep 2023 Discontinued - Preclinical for Cancer in Singapore (Parenteral) (ASLAN Pharmaceuticals pipeline, September 2023)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Cancer in Singapore (Parenteral)
- 01 Sep 2016 Preclinical trials in Cancer in Singapore (unspecified route)